It has been reported that if organs with crucial functions, including the liver, neurons, and kidneys, express the same antigens targeted by
immunotoxins, they will undergo
immunotoxin-induced injury.
Because a variety of disorders are treated with bone marrow transplants, the use of
immunotoxins to eliminate harmful cells prior to the procedure could have a significant impact in increasing transplant success rates and reducing hospital time.
Recombinant anti-CD25
immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
The
immunotoxins have lived up to their billing as cancer killers, but they also trigger changes in cells lining blood vessels.
Use of such lines for the production of ricin for use in
immunotoxins should offer a significant advantage, since RCA proteins must be removed during the purification of ricin (Ghetie and Vitetta, 1994).
Eradication of tumor colonization and invasion by a B cell specific
immunotoxin in a murine model for human primary intraocular lymphoma.
GCR-3888 has demonstrated the potential opportunity from utilizing this
immunotoxin approach in HCL and we look forward to exploring the mechanism in a wider range of B-cell malignancies, including NHL and CLL, and to working in collaboration with the NCI.
The ability of LMB-9 to kill tumor cells at very low concentrations, as well as favorable results from our ongoing clinical trial with TP-38 in brain cancer, encouraged IVAX in this important expansion of our
immunotoxin platform.
Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM (1991) Production of a pokeweed antiviral protein (PAP)-containing
immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
0, and further comprising a specified amino-terminal amino acid sequence, as well as to a conjugate of said protein with a targeting ligand, such as an antibody, to form an
immunotoxin.
Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain
immunotoxin does not impair in vitro antileukemia and antiviral activity.
Anderson Hospital and Tumor Institute in Houston, suggests that linking those antibodies to substances that are toxic to cells will form an
immunotoxin capable of selectively destroying cancer cells.
